The drug experiment not only confirmed the important role of ribosome biogenesis in Kmt2d‐deficiency‐induced AML, but also suggested a potential therapeutic target for KMT2D low‐expression or mutated AML patients. The gene discussed is KMT2D; the disease is acute myeloid leukemia.